Cidara Therapeutics Inc. clinical trials
Acquired by Merck & Co., Inc, Jan 7, 2026 · source ↗
The registry lists 13 studies whose lead sponsor is Cidara Therapeutics Inc.. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 6, 2026.
- 13studies on the registry
- 2open to participants now
- 1phase 3 study under way
- 3reach primary completion within a year
Before and after it joined Merck & Co., Inc
- First submitted before Cidara Therapeutics Inc. became part of Merck & Co., Inc
- 13
- First submitted after Cidara Therapeutics Inc. became part of Merck & Co., Inc
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Cidara Therapeutics Inc.’s studies test, most open studies first — 2 drugs with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
- MK-14061 in phase 32 open · 4
- Rezafungin1 in phase 30 open · 5
Coming up
3 of Cidara Therapeutics Inc.’s studies under way reach primary completion within a year, 1 of them phase 3. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- 1DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- 1JJun
- 1JJul
- AAug
- SSep
- OOct
- NNov
All 3
- Dec 2026A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)MK-1406 · NCT07300085
- Jun 2027A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)MK-1406 · Phase 3 · NCT07159763
- Jul 2027A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)MK-1406 · NCT07225959
Add all 3 to your calendar (.ics) → With an account.
What changed recently
From the registry's own updates since Oct 14, 2026.
Started recruiting2
All 13 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 15
- 316
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Cidara Therapeutics Inc.9 studies
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)4 studies
Something wrong with this grouping? Tell us on the Merck & Co., Inc page.
Studies
Recruiting first, then most recently updated. Showing 13 of 13. All Merck & Co., Inc studies →
- A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)RecruitingNCT07159763Phase 3
Sponsor listed in the registry: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cidara Therapeutics Inc. became part of Merck & Co., Inc
- A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)RecruitingNCT07300085Phase 1
Sponsor listed in the registry: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cidara Therapeutics Inc. became part of Merck & Co., Inc
- A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)Active, not recruitingNCT07225959Phase 2
Sponsor listed in the registry: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cidara Therapeutics Inc. became part of Merck & Co., Inc
- Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza ComplicationsCompletedNCT06609460Phase 2
Sponsor listed in the registry: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Cidara Therapeutics Inc. became part of Merck & Co., Inc
- Study of CD388 Intramuscular or Subcutaneous Administration in Healthy SubjectsCompletedNCT05285137Phase 1
Sponsor listed in the registry: Cidara Therapeutics Inc. · First submitted before Cidara Therapeutics Inc. became part of Merck & Co., Inc
- Study of CD388 Subcutaneous Administration in Healthy Japanese SubjectsCompletedNCT05619536Phase 1
Sponsor listed in the registry: Cidara Therapeutics Inc. · First submitted before Cidara Therapeutics Inc. became part of Merck & Co., Inc
- The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy AdultsCompletedNCT05523089Phase 2
Sponsor listed in the registry: Cidara Therapeutics Inc. · First submitted before Cidara Therapeutics Inc. became part of Merck & Co., Inc
- A Single Ascending Dose Study of CD101 IV in Healthy SubjectsCompletedNCT02516904Phase 1
Sponsor listed in the registry: Cidara Therapeutics Inc. · First submitted before Cidara Therapeutics Inc. became part of Merck & Co., Inc
- Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive CandidiasisCompletedNCT03667690Phase 3
Sponsor listed in the registry: Cidara Therapeutics Inc. · First submitted before Cidara Therapeutics Inc. became part of Merck & Co., Inc
- CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging ExtensionCompletedNCT02734862Phase 2
Sponsor listed in the registry: Cidara Therapeutics Inc. · First submitted before Cidara Therapeutics Inc. became part of Merck & Co., Inc
- RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast InfectionsCompletedNCT02733432Phase 2
Sponsor listed in the registry: Cidara Therapeutics Inc. · First submitted before Cidara Therapeutics Inc. became part of Merck & Co., Inc
- Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida ColonizationCompletedNCT02888197
Sponsor listed in the registry: Cidara Therapeutics Inc. · First submitted before Cidara Therapeutics Inc. became part of Merck & Co., Inc
- An Ascending Multiple Dose Study of CD101 IV in Healthy SubjectsCompletedNCT02551549Phase 1
Sponsor listed in the registry: Cidara Therapeutics Inc. · First submitted before Cidara Therapeutics Inc. became part of Merck & Co., Inc